Pegcetacoplan (EMPAVELI®) para la hemoglobinuria paroxística nocturna

Comisión Nacional de Evaluación de Tecnologías de Salud (CONETEC) (CONETEC).
s.l; CONETEC; 2 jun. 2022.
Não convencional Espanhol | BRISA | ID: biblio-1381059

Documentos relacionados

  1. Compstatins: the dawn of clinical C3-targeted complement inhibition.
  2. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.
  3. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
  4. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
  5. Pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
  6. Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
  7. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
  8. [Current treatment of paroxysmal nocturnal hemoglobinuria and prospects for new therapeutic agents in the future].
  9. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
  10. With complements: C3 inhibition in the clinic.